AR065896A1 - Formas cristalinas de [3-(4-{2 butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]dietil-amina - Google Patents

Formas cristalinas de [3-(4-{2 butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]dietil-amina

Info

Publication number
AR065896A1
AR065896A1 ARP080101342A ARP080101342A AR065896A1 AR 065896 A1 AR065896 A1 AR 065896A1 AR P080101342 A ARP080101342 A AR P080101342A AR P080101342 A ARP080101342 A AR P080101342A AR 065896 A1 AR065896 A1 AR 065896A1
Authority
AR
Argentina
Prior art keywords
penoxi
dietil
propil
butil
amina
Prior art date
Application number
ARP080101342A
Other languages
English (en)
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of AR065896A1 publication Critical patent/AR065896A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)

Abstract

Procesos de obtencion y composiciones farmacéuticas que los contienen. Reivindicacion 1: Un polimorfo de compuesto 1, Forma 1, que tiene un espectro de 13C RMN de estado solido que comprende picos en 149,7 y 141, ppm.
ARP080101342A 2007-04-05 2008-03-31 Formas cristalinas de [3-(4-{2 butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]dietil-amina AR065896A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92196407P 2007-04-05 2007-04-05
US92578607P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
AR065896A1 true AR065896A1 (es) 2009-07-08

Family

ID=39469930

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101342A AR065896A1 (es) 2007-04-05 2008-03-31 Formas cristalinas de [3-(4-{2 butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]dietil-amina

Country Status (11)

Country Link
US (2) US7884219B2 (es)
EP (1) EP2144883A1 (es)
JP (1) JP2010523559A (es)
AR (1) AR065896A1 (es)
CA (1) CA2681864A1 (es)
CL (1) CL2008000987A1 (es)
PA (1) PA8775601A1 (es)
PE (1) PE20090808A1 (es)
TW (1) TW200900384A (es)
UY (1) UY31004A1 (es)
WO (1) WO2008123914A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008123914A1 (en) * 2007-04-05 2008-10-16 Transtech Pharma, Inc. Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
CA2886785C (en) * 2012-10-05 2022-06-07 Transtech Pharma, Llc Treatment of mild and moderate alzheimer's disease
US9717710B2 (en) * 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
CN103726005A (zh) * 2012-10-16 2014-04-16 深圳富泰宏精密工业有限公司 珐琅涂层的制造方法及其制品
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) * 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613321A (zh) * 2002-03-05 2009-12-30 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2008123914A1 (en) * 2007-04-05 2008-10-16 Transtech Pharma, Inc. Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Also Published As

Publication number Publication date
US20110166361A1 (en) 2011-07-07
US7884219B2 (en) 2011-02-08
US20080249316A1 (en) 2008-10-09
JP2010523559A (ja) 2010-07-15
EP2144883A1 (en) 2010-01-20
TW200900384A (en) 2009-01-01
WO2008123914A1 (en) 2008-10-16
PE20090808A1 (es) 2009-06-27
PA8775601A1 (es) 2009-04-23
US8372988B2 (en) 2013-02-12
CA2681864A1 (en) 2008-10-16
UY31004A1 (es) 2008-11-28
CL2008000987A1 (es) 2008-08-08

Similar Documents

Publication Publication Date Title
AR065896A1 (es) Formas cristalinas de [3-(4-{2 butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]dietil-amina
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
ECSP10010722A (es) Compuestos orgánicos
CR11492A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
NO20080784L (no) Histondeacetylaseinhibitorer
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
MY153971A (en) Sulfonamides as trpm8 modulators
CL2012003564A1 (es) Compuestos derivados de heteroaril limidazolona :composición farmacéutica;uso de los compuestos para la inhibición de jak1,jak2 y jak3; y combinaciones farmacéuticas.
EA201000269A1 (ru) Новые гербициды
CU20060037A7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
DK1954690T3 (da) Benzamidforbindelser, der er anvendelige som inhibitorer af histondeacetylase
ATE483000T1 (de) Naphtalin-amidin-imide
EA200900945A1 (ru) Новый способ синтеза агомелатина
EA201101148A1 (ru) Новые гербициды
CL2008000784A1 (es) Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
DE602006009789D1 (de) Acetylenderivate
EA200900946A1 (ru) Новый способ синтеза агомелатина
WO2011053035A3 (ko) 유기발광화합물 및 이를 구비한 유기발광소자
EA200900397A1 (ru) Новые соединения диосметина, способ их получения и фармацевтические композиции, которые их содержат
EA201100920A1 (ru) Новые гербициды
BR112013001111A2 (pt) processo para a produção do composto da fórmula 1, processo para a produção de um composto da fórmula a, processo para a produção dos compostos da fórmula d, composto da fórmula e, composto da fórmula f e novos compostos
CU20090009A7 (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
WO2009074741A3 (fr) Nouveau procede de synthese du ranelate de strontium et de ses hydrates
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser

Legal Events

Date Code Title Description
FB Suspension of granting procedure